Compare AstraZeneca plc (AZN) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Kimberly Clark Corp — how do they compare? AstraZeneca plc trades at $168.36 (market cap $253.13B), while Kimberly Clark Corp trades at $106.42 (market cap $35.46B). The key difference: AstraZeneca plc is far larger — about 7.1× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (4.79%). Which is the better fit depends on your goals.
| AZN | KMB | |
|---|---|---|
Market Cap | $253.13B | $35.46B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $136.77 |
52-Week Low | $137.44 | $93.05 |
Enterprise Value | $279.37B | $42.00B |
Dividend Yield | 1.92% | 4.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Kimberly-Clark (KMB) trades at $110.18, down 1.98% on the day, with strong technical support at $108 and resistance at $114. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $1.97 versus $1.93, maintaining a consistent earnings beat streak. Recent business developments include the Arbex joint venture launch and pending Kenvue acquisition, positioning for strategic growth in the consumer goods sector.
KMB offers stable dividend income with a 4.5% yield and strong profitability metrics (12.8% net margin, 146.29% ROE), though elevated P/E (21.31) and P/B (20.36) ratios suggest premium valuation. Risks include consumer sentiment pressures and input cost inflation, but analyst consensus targets $112.33 with 32% buy ratings supporting moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
